SciSparc's NeuroThera Labs Files Depression Therapy Patent Application with Clearmind Medicine
SPRC sits 20% above its 52-week low of $3.6 on light trading volume (0.3× avg).
Summary
SciSparc's majority-owned subsidiary, NeuroThera Labs, has filed a patent application for a depression therapy, stemming from its collaboration with Clearmind Medicine. This development signifies progress in SciSparc's product pipeline and intellectual property portfolio. For a micro-cap biotech company, securing patents for potential therapies is a crucial step in validating its research and development efforts and can be a significant long-term value driver. This news follows NeuroThera Labs' recent acquisition of a majority stake in CliniQuantum and the publication of another international patent application earlier this month, indicating active development. Investors will be watching for updates on the patent's approval and any subsequent clinical trial advancements for this therapy.
At the time of this announcement, SPRC was trading at $4.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $3.60 to $94.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.